Pune, India, June 06, 2023 (GLOBE NEWSWIRE) — The global Opioid Use Disorder (OUD) market size was valued at USD 3.10 billion in 2022. The market is projected to grow from USD 3.35 billion in 2023 to USD 6.14 billion by 2030, exhibiting a CAGR of 9.1% during the forecast period. The rise is due to the increasing formulation of regulatory policies for addressing the condition. The treatment constitutes three drug classes – buprenorphine, methadone, and naltrexone.
This information is presented by Fortune Business Insights, in its report titled, “Opioid Use Disorder (OUD) Market, 2023-2030.”
Request a Free Sample Copy of the Research Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/opioid-use-disorder-oud-market-102674
Key Industry Development:
March 2022: Collegium Pharmaceutical, Inc. declared that it has successfully accomplished the acquisition of BioDelivery Sciences International Inc.
Key Takeaways:
- In order to create a clinical trial for the creation of a Lidocaine patch for OUD treatment, WellSpan Health teamed up with York Opioid Collaboration in 2019.
- In 2021, the CDC reported that approximately 2.7 million individuals aged 12 or older in the United States disclosed having OUD.
- The market is divided into three categories based on drug class: methadone, buprenorphine, and naltrexone
- The hospital pharmacies segment is expected to dominate due to its significant reliance on this channel
Discover the Leading Players Featured in the Report:
Indivior PLC (U.S.), Alkermes (Ireland) , Orexo AB (Sweden), Titan Pharmaceuticals, Inc. (U.S.) ,Mallinckrodt Pharmaceuticals (U.K) , BioDelivery Sciences International Inc. (U.S. , Viatris Inc. (Mylan N.V.) (U.S.), Hikma Pharmaceuticals PLC (U.K.), Camurus (Sweden)
Report Scope & Segmentation
| Report Coverage | Details |
| Forecast Period | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR | 9.1% |
| 2030 Value Projection | USD 6.14 billion |
| Base Year | 2022 |
| Market Size in 2023 | USD 3.35 billion |
| Historical Data | 2019-2021 |
| No. of Pages | 129 |
| Segments covered | By Drug Class, Route of Administration, Distribution Channel, and Region |
Browse Complete Report Details: https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674
Driving factor:
Increasing Cases of Opioid Addiction to Drive the OUD Market Growth
A vast variety of severe and chronic diseases, such as cancer, cardiovascular disease, pain from injuries, and other ailments, affect the general population today. Patients with these disorders frequently have chronic pain, which is generally treated by taking medications, primarily opioids. While the pain diminishes, there is a higher possibility that the patient will become dependent on these drugs. The patient may have withdrawal symptoms as a result of their increasing dependence on these medications and abrupt termination.
Segmentation:
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Region
North America
Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South East Asia
Regional insights:
North America to Hold Lion’s Share Backed by the Presence of Key Players
North America, which had a market value of USD 2.39 billion in 2022, is expected to hold a commanding position during the forecast period due to the significant number of Americans who suffer from opioid dependency, the presence of major players in the region, and the growing involvement of the government in combating the pandemic.
According to projections, Europe will come in second in terms of the global market share. This can be attributed to the region’s increased new product launches as well as rise in patients with opioid dependence.
Quick Buy – https://www.fortunebusinessinsights.com/checkout-page/102674
Competitive Landscape
Acquisitions Initiated by Key Opioid Use Disorder (OUD) Companies to Promote Market Growth
The leading Opioid Use Disorder (OUD) players in the market constantly opt for efficient strategies to bolster their brand value as well as promote global market growth. One such efficient strategy is acquiring competitive companies and further securing a profit for both companies. For instance, in February 2021, Orexo AB collaborated with ApexB.io and Magellan Rx Management for further research use of Modia.
FAQ’s
How big is the opioid use disorder market?
The opioid use disorder market size is USD 3.35 Billion in 2023.
How fast is the opioid use disorder market growing?
The opioid use disorder market will exhibit a CAGR of 9.1% during the forecast period, 2023-2030
Have Any Query? Ask Our Experts:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/opioid-use-disorder-oud-market-102674
Related Links:
SUBSTANCE ABUSE TREATMENT Market Size, Share, Growth Industry Report
Drugs Of Abuse Testing Market Share, Size, Demand, and Forecast
Addiction Treatment Market Size, Share, Growth Industry Report
Chronic Lower Back Pain Treatment Market Share, Size, Demand, and Forecast
Parkinson’s Disease Drugs Market Size, Share, Growth Industry Report
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.